| __timestamp | Catalyst Pharmaceuticals, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 7751000 |
| Thursday, January 1, 2015 | 8597010 | 10251000 |
| Friday, January 1, 2016 | 7910260 | 9575000 |
| Sunday, January 1, 2017 | 7304399 | 10912000 |
| Monday, January 1, 2018 | 15875961 | 11049000 |
| Tuesday, January 1, 2019 | 36881187 | 11646000 |
| Wednesday, January 1, 2020 | 44233754 | 13265000 |
| Friday, January 1, 2021 | 49628000 | 25805000 |
| Saturday, January 1, 2022 | 58183000 | 35182000 |
| Sunday, January 1, 2023 | 133710000 | 94999000 |
In pursuit of knowledge
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Catalyst Pharmaceuticals and Viridian Therapeutics have shown distinct approaches to handling these costs. From 2014 to 2023, Catalyst Pharmaceuticals saw a significant increase in SG&A expenses, peaking at approximately 133.7 million in 2023, a nearly 30-fold increase from 2014. In contrast, Viridian Therapeutics managed a more moderate rise, with expenses reaching around 94.9 million in 2023, reflecting a 12-fold increase from 2014. This data suggests that while both companies have expanded their operations, Catalyst Pharmaceuticals has experienced a more aggressive growth in SG&A costs. Understanding these trends can provide valuable insights for investors and stakeholders looking to evaluate the financial health and strategic priorities of these companies.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Dr. Reddy's Laboratories Limited vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Pharming Group N.V. vs Catalyst Pharmaceuticals, Inc. Trends and Insights
Verona Pharma plc or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and Viridian Therapeutics, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc.: SG&A Spending Patterns Compared
Protagonist Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Ligand Pharmaceuticals Incorporated and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared